Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proof-of-concept open-label study of batoclimab in Graves' disease
2022-002894-27Phase 2Active
- Sponsor
- Immunovant, Inc.
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of batoclimab in Graves' disease, sponsored by Immunovant, Inc. Primary endpoint: Proportion of participants with normalized or reduced FT3/FT4 at Week 24 without ATD dose increase. Started Nov 2022; status: active.
02
Drugs
batoclimab
03
Conditions
Graves' disease
Beyond the preview
Go deeper on 2022-002894-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002894-27.